Viemed Healthcare, Inc. (VMD)

From the record

Viemed Healthcare, Inc.'s filings since 2018 show 1 warning event: a warning not to rely on past financial statements (8-K item 4.02, the latest 2020-03-03) (its current reports).

From the record

Viemed Healthcare, Inc.'s 8 filed years say what it did: revenue went from $64 million in fiscal 2018 to $270 million in fiscal 2025, up 22.7% a year; it rose in 6 of 7 years; the deepest fall was 11% from fiscal 2020 to fiscal 2021; net income was positive in 8 of 8 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Viemed Healthcare, Inc.'s diluted share count grew about 0.8% a year, and dividends and buybacks returned about 10% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 9 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Viemed Healthcare, Inc. earned about 11 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 78 cents per dollar of everything the company owns. Leverage: it owed about 29 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).

From the record

Viemed Healthcare, Inc.'s standing among 10 graded names in its industry family: revenue of $270 million in fiscal 2025 ranks in the top 50% by size; a net margin of 5.5% ranks in the top 35%; revenue growth of 24.9% a year over the last 3 filed years ranks in the top 35% (its annual reports).

From the record

Viemed Healthcare, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Hoyt, Casey (Chief Executive Officer, as filed), filing under that title since 2020-12-31, 5.9 years (top 44% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 5.9 years (top 50%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 50%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Viemed Healthcare, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $14 million against debt of $11 million leaves 1.1% of its assets as net cash, bottom 45% of its family; cash from operations less capital spending is 4.4% of revenue (bottom 45%); a gross margin of 57.5% (top 31%); research spending of 1.1% of revenue (top 50%) (its annual report).

From the record

Viemed Healthcare, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 24.9% a year over the last three filed years against 22.7% over all 8, speeding up (top 25% of its family); the newest year grew 20.5% (top 5%); research spending grew 3.8% a year (top 37%); capital spending grew 20.4% a year (top 15%) (its annual reports). Viemed Healthcare, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Viemed Healthcare, Inc.'s newest year against its own record: revenue of $270 million in fiscal 2025 came in 5.2% below the $285 million its prior three years' pace pointed to (top 45% of its family); net income of $15 million against a prior three-year average of $9 million (top 25%); a net margin of 5.5% against 5% before (bottom 45%) (its annual reports).